Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)

The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: OZHAROVSKAIA Tatiana Andreevna, Tokarskaia Elizaveta Aleksandrovna, Kriukov Evgenii Vladimirovich, Kutaev Dmitrii Anatolevich, ZUBKOVA Olga Vadimovna, Chernetsov Vladimir Aleksandrovich, Erokhova Alina Sergeevna, DOLZHIKOVA Inna Vadimovna, IZHAEVA Fatima Magomedovna, POPOVA Olga, SHCHERBININ Dmitrii Nikolaevich, BOTIKOV Andrei Gennadevich, SHCHEBLIAKOV Dmitrii Viktorovich, Nikitenko Natalia Anatolevna, Babira Vladimir Fedorovich, TUKHVATULIN Amir Ildarovich, ESMAGAMBETOV Ilias Bulatovich, SEMIKHIN Aleksandr Sergeevich, Dzharullaeva Alina Shakhmirovna, GINTSBURG Aleksandr Leonidovich, Loginova Svetlana Iurevna, Naroditskii Boris Savelevich, TUKHVATULINA Natalia Mikhailovna, LUBENETS Nadezhda Leonidovna, Logunov Denis Iurevich, GROUSOVA Daria Mikhailovna
Format: Patent
Sprache:eng ; heb
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subje